Plain-English translation of NCT04514965 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Primary biliary cholangitis is a rare liver disease where the body's immune system damages the bile ducts, potentially leading to liver damage over time. This trial tests bezafibrate, a medication that has shown promise in early studies as an add-on treatment for patients whose liver disease isn't controlled well enough by standard therapy alone. Researchers want to understand how the medication works and whether it can improve outcomes for people in this situation.
About 40% of patients with this disease don't respond well enough to the current standard treatment, and their long-term outlook is worse. This trial exists to see whether this medication, which has been safely used for other conditions for many years, can help people who need more effective treatment options.
You likely qualify if…
You likely don't qualify if…
You will start taking the medication and visit the clinic before treatment begins, then at 4 weeks, 6 months, 1 year, 2 years, and 3 years after starting. At each visit, you'll have blood tests drawn and a quick ultrasound-like scan (FibroScan) to check your liver stiffness, and you'll be asked about any itching you may experience. The study tracks how your body responds to the treatment over three years.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Denmark